Tarsus Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Tarsus Pharmaceuticals announced significant year-over-year revenue growth in Q2 2026, driven by XDEMVY sales, and provided updates on its promising pipeline candidates.
NASDAQ
Tarsus Pharmaceuticals reported a significant increase in product sales for Q1 2026, driven by XDEMVY, while narrowing its net loss compared to the prior year.
NASDAQ
Tarsus Pharmaceuticals announced significant revenue growth for its lead product XDEMVY in Q3 2025, alongside continued operating losses and strategic pipeline advancements.
NASDAQ
Tarsus Pharmaceuticals announced a significant increase in product sales for XDEMVY, reducing net losses while advancing its pipeline candidates.
NASDAQ
Tarsus Pharmaceuticals' Q1 2025 revenue surged, fueled by a significant increase in XDEMVY sales, alongside strategic financial moves to bolster its market position.
NASDAQ
Tarsus Pharmaceuticals reports a significant increase in product sales for Q3 2024, primarily driven by the commercialization of XDEMVY.
NASDAQ
Tarsus Pharmaceuticals saw a significant increase in revenue during the second quarter of 2024, primarily driven by the commercial success of its product XDEMVY.
NASDAQ
Tarsus Pharmaceuticals reports a significant increase in first quarter 2024 revenue, primarily driven by the commercial success of its Demodex blepharitis treatment, XDEMVY.